OVID insider transaction filings
Ovid Therapeutics Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-08. Screen OVID transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Carter Charles Ross — Chief Financial Officer | 1 | — | — | 1 |
Recent Form 4 filings — Ovid Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Carter Charles Ross — Chief Financial Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-06-17 | 4 | Greka Anna — Director | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Fitzgerald Kevin Joseph — Director | Grant/award (A): 17,578 @ $2.56 | EDGAR |
| 2026-04-09 | 4 | Friedman Bart — Director | Grant/award (A): 8,789 @ $2.56 | EDGAR |
| 2026-04-09 | 4 | PAPADOPOULOS STELIOS — Director | Grant/award (A): 17,578 @ $2.56 | EDGAR |
| 2026-03-25 | 4 | LEVIN JEREMY M — Executive Chairman, Director | Option exercise (M): 47,333 @ $1.40 · Option exercise (M): 47,333 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | ALEXANDER MARGARET A. — President and CEO, Director | Sale (S): 11,656 @ $1.45 · Grant/award (A): 1,435,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Fitzgerald Kevin Joseph — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Bernstein Karen — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Friedman Bart — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | DUNCAN BARBARA GAYLE — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Rona Jeffrey A — CBFO | Sale (S): 8,541 @ $1.45 · Grant/award (A): 68,125 @ $0 · Grant/award (A): 408,750 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | LEVIN JEREMY M — Director | Grant/award (A): 957,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | PAPADOPOULOS STELIOS — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | ALEXANDER MARGARET A. — President and CEO, Director | Grant/award (A): 890,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | LEVIN JEREMY M — CEO, Director | Conversion (C): 71,000 · Purchase (P): 71 (derivative) · Purchase (P): 47,333 (derivative) · Purchase (P): 35,500 (derivative) · Conversion (C): 71 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | TAKEDA PHARMACEUTICAL CO LTD — 10% owner Takeda Pharmaceuticals U.S.A., Inc. — 10% owner | Conversion (C): 1,250,000 @ $0 · Conversion (C): 1,250 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Fitzgerald Kevin Joseph — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Bernstein Karen — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Friedman Bart — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Duncan Barbara Gayle — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | PAPADOPOULOS STELIOS — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | ALEXANDER MARGARET A. — President and COO | Sale (S): 5,279 @ $0.56 | EDGAR |
| 2025-02-28 | 4 | Rona Jeffrey A — CBFO | Sale (S): 3,902 @ $0.56 | EDGAR |
| 2025-02-24 | 4 | ALEXANDER MARGARET A. — President and COO | Grant/award (A): 43,750 @ $0 · Grant/award (A): 262,500 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Rona Jeffrey A — CBFO | Grant/award (A): 43,750 @ $0 · Grant/award (A): 262,500 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | LEVIN JEREMY M — CEO, Director | Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | ALEXANDER MARGARET A. — President and COO | Purchase (P): 6,810 @ $0.73 | EDGAR |
| 2024-12-16 | 4 | Fitzgerald Kevin Joseph — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | Bernstein Karen — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | Friedman Bart — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | Duncan Barbara Gayle — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-09-11 | 4 | ALEXANDER MARGARET A. — President and COO | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-08-01 | 4 | Rona Jeffrey A — CBFO | Grant/award (A): 315,000 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | LEVIN JEREMY M — CEO, Director | Purchase (P): 18,248 @ $2.76 | EDGAR |
| 2024-02-26 | 4 | Perone Thomas Michael — General Counsel, Secretary | Grant/award (A): 28,125 @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Tardio Jason — Chief Operating Officer | Grant/award (A): 28,125 @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Poole Robert Michael — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Fitzgerald Kevin Joseph — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Bernstein Karen — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Friedman Bart — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Duncan Barbara Gayle — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Rona Jeffrey A — CBFO | Grant/award (A): 28,125 @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | LEVIN JEREMY M — CEO, Director | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4/A | LEVIN JEREMY M — CEO, Director | Gift (G): 465,116 @ $0 | EDGAR |
Recent 8-K events — Ovid Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-12 | 8-K | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OVID returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →